Cargando…
Early Use of Sarilumab in Patients Hospitalized with COVID-19 Pneumonia and Features of Systemic Inflammation: the SARICOR Randomized Clinical Trial
The objective of this study was to investigate the efficacy and safety of early treatment with sarilumab, added to standard of care (SOC), in hospitalized adults with COVID-19. Methods included phase II, open-label, randomized, controlled clinical trial of hospitalized patients with COVID-19 pneumon...
Autores principales: | Merchante, Nicolás, Cárcel, Sheila, Garrido-Gracia, José Carlos, Trigo-Rodríguez, Marta, Moreno, María Ángeles Esteban, León-López, Rafael, Espíndola-Gómez, Reinaldo, Alonso, Eduardo Aguilar, García, David Vinuesa, Romero-Palacios, Alberto, Pérez-Camacho, Inés, Gutiérrez-Gutiérrez, Belén, Martínez-Marcos, Francisco Javier, Fernández-Roldán, Concepción, Pérez-Crespo, Pedro María Martínez, Caño, Alexandra Aceituno, León, Eva, Corzo, Juan E., de la Fuente, Carmen, Torre-Cisneros, Julián |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8846457/ https://www.ncbi.nlm.nih.gov/pubmed/34902262 http://dx.doi.org/10.1128/aac.02107-21 |
Ejemplares similares
-
Role of IP-10 to Predict Clinical Progression and Response to IL-6 Blockade With Sarilumab in Early COVID-19 Pneumonia. A Subanalysis of the SARICOR Clinical Trial
por: Trigo-Rodríguez, Marta, et al.
Publicado: (2023) -
Efficacy and safety of early treatment with sarilumab in hospitalised adults with COVID-19 presenting cytokine release syndrome (SARICOR STUDY): protocol of a phase II, open-label, randomised, multicentre, controlled clinical trial
por: León López, Rafael, et al.
Publicado: (2020) -
Inhibition of Human Coronaviruses by Combinations of Host-Targeted and Direct-Acting Antivirals
por: de León, Patricia, et al.
Publicado: (2023) -
Atypical Mutational Spectrum of SARS-CoV-2 Replicating in the Presence of Ribavirin
por: Somovilla, Pilar, et al.
Publicado: (2023) -
Pharmacological Elevation of Cellular Dihydrosphingomyelin Provides a Novel Antiviral Strategy against West Nile Virus Infection
por: Jiménez de Oya, Nereida, et al.
Publicado: (2023)